Weshalb die Actinium Pharmaceuticals-Aktie
ein D-Rating hat,
erfahren Sie im Performance-Check
vom 14. November 2025 Info.
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2022 | 5,30 | 9,63 | 81,70% |
| 2 | 2020 | 5,30 | 6,75 | 27,36% |
| 3 | 2025 | 1,16 | 1,09 | -6,03% |
| 4 | 2021 | 6,75 | 5,30 | -21,48% |
| 5 | 2019 | 7,83 | 5,30 | -32,31% |
| 6 | 2017 | 25,23 | 16,59 | -34,24% |
| 7 | 2015 | 155,31 | 84,00 | -45,91% |
| 8 | 2018 | 16,59 | 7,83 | -52,80% |
| 9 | 2023 | 9,63 | 4,46 | -53,69% |
| 10 | 2016 | 84,00 | 25,23 | -69,96% |
| 11 | 2024 | 4,46 | 1,16 | -73,99% |
| Rang | Datum | Vorjahr | Schluss | Performance |
|---|---|---|---|---|
| 1 | 2024 | 4,46 | 1,16 | -73,99% |
| 2 | 2016 | 84,00 | 25,23 | -69,96% |
| 3 | 2023 | 9,63 | 4,46 | -53,69% |
| 4 | 2018 | 16,59 | 7,83 | -52,80% |
| 5 | 2015 | 155,31 | 84,00 | -45,91% |
| 6 | 2017 | 25,23 | 16,59 | -34,24% |
| 7 | 2019 | 7,83 | 5,30 | -32,31% |
| 8 | 2021 | 6,75 | 5,30 | -21,48% |
| 9 | 2025 | 1,16 | 1,09 | -6,03% |
| 10 | 2020 | 5,30 | 6,75 | 27,36% |
| 11 | 2022 | 5,30 | 9,63 | 81,70% |